- Home
- PRLD vs ICCM Comparison
PRLD vs ICCM Comparison
Compare PRLD & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- ICCM
- Stock Information
- Founded
- PRLD 2016
- ICCM 2006
- Country
- PRLD United States
- ICCM Israel
- Employees
- PRLD N/A
- ICCM N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- ICCM
- Sector
- PRLD Health Care
- ICCM
- Exchange
- PRLD Nasdaq
- ICCM Nasdaq
- Market Cap
- PRLD 69.1M
- ICCM 61.1M
- IPO Year
- PRLD 2020
- ICCM N/A
- Fundamental
- Price
- PRLD $1.42
- ICCM $0.99
- Analyst Decision
- PRLD Strong Buy
- ICCM Strong Buy
- Analyst Count
- PRLD 3
- ICCM 1
- Target Price
- PRLD $4.00
- ICCM $2.50
- AVG Volume (30 Days)
- PRLD 290.5K
- ICCM 2.5M
- Earning Date
- PRLD 11-05-2025
- ICCM 11-25-2025
- Dividend Yield
- PRLD N/A
- ICCM N/A
- EPS Growth
- PRLD N/A
- ICCM N/A
- EPS
- PRLD N/A
- ICCM N/A
- Revenue
- PRLD $7,000,000.00
- ICCM $2,787,000.00
- Revenue This Year
- PRLD N/A
- ICCM $3.95
- Revenue Next Year
- PRLD N/A
- ICCM $266.15
- P/E Ratio
- PRLD N/A
- ICCM N/A
- Revenue Growth
- PRLD N/A
- ICCM N/A
- 52 Week Low
- PRLD $0.61
- ICCM $0.48
- 52 Week High
- PRLD $2.08
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- PRLD 60.29
- ICCM 47.07
- Support Level
- PRLD $1.33
- ICCM $0.93
- Resistance Level
- PRLD $1.63
- ICCM $1.40
- Average True Range (ATR)
- PRLD 0.18
- ICCM 0.07
- MACD
- PRLD 0.01
- ICCM -0.01
- Stochastic Oscillator
- PRLD 49.42
- ICCM 12.79
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.